Annual FCF
$220.11 M
-$56.28 M-20.36%
December 31, 2024
Summary
- As of March 12, 2025, AMRX annual free cash flow is $220.11 million, with the most recent change of -$56.28 million (-20.36%) on December 31, 2024.
- During the last 3 years, AMRX annual FCF has risen by +$30.93 million (+16.35%).
- AMRX annual FCF is now -29.64% below its all-time high of $312.81 million, reached on December 31, 2020.
Performance
AMRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
$95.01 M
-$26.05 M-21.52%
December 31, 2024
Summary
- As of March 12, 2025, AMRX quarterly free cash flow is $95.01 million, with the most recent change of -$26.05 million (-21.52%) on December 31, 2024.
- Over the past year, AMRX quarterly FCF has stayed the same.
- AMRX quarterly FCF is now -60.35% below its all-time high of $239.63 million, reached on December 31, 2018.
Performance
AMRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
$220.11 M
-$9.12 M-3.98%
December 31, 2024
Summary
- As of March 12, 2025, AMRX TTM free cash flow is $220.11 million, with the most recent change of -$9.12 million (-3.98%) on December 31, 2024.
- Over the past year, AMRX TTM FCF has stayed the same.
- AMRX TTM FCF is now -46.00% below its all-time high of $407.64 million, reached on March 31, 2021.
Performance
AMRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
AMRX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.4% | 0.0% | 0.0% |
| 3 y3 years | +16.4% | +114.8% | +313.2% |
| 5 y5 years | +329.9% | +28.1% | -29.6% |
AMRX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -20.4% | +963.3% | -25.8% | +166.6% | -20.4% | +963.3% |
| 5 y | 5-year | -29.6% | +329.9% | -44.3% | +166.6% | -46.0% | +329.9% |
| alltime | all time | -29.6% | +329.9% | -60.4% | +166.6% | -46.0% | +298.0% |
Amneal Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $220.11 M(-20.4%) | $95.01 M(-21.5%) | $220.11 M(-4.0%) |
| Sep 2024 | - | $121.06 M(+329.3%) | $229.23 M(+30.2%) |
| Jun 2024 | - | $28.20 M(-216.7%) | $176.07 M(+41.7%) |
| Mar 2024 | - | -$24.17 M(-123.2%) | $124.24 M(-55.0%) |
| Dec 2023 | $276.39 M(-1184.1%) | $104.13 M(+53.3%) | $276.39 M(+101.0%) |
| Sep 2023 | - | $67.91 M(-387.4%) | $137.50 M(+20.8%) |
| Jun 2023 | - | -$23.63 M(-118.5%) | $113.83 M(-2296.6%) |
| Mar 2023 | - | $127.97 M(-468.2%) | -$5.18 M(-79.7%) |
| Dec 2022 | -$25.50 M(-113.5%) | -$34.76 M(-178.6%) | -$25.50 M(-147.9%) |
| Sep 2022 | - | $44.24 M(-131.0%) | $53.27 M(-33.2%) |
| Jun 2022 | - | -$142.64 M(-232.5%) | $79.76 M(-50.6%) |
| Mar 2022 | - | $107.66 M(+144.6%) | $161.41 M(-14.7%) |
| Dec 2021 | $189.18 M | $44.01 M(-37.8%) | $189.18 M(-13.7%) |
| Sep 2021 | - | $70.73 M(-216.0%) | $219.34 M(+24.7%) |
| Jun 2021 | - | -$60.99 M(-145.0%) | $175.96 M(-56.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $135.44 M(+82.6%) | $407.64 M(+30.3%) |
| Dec 2020 | $312.81 M(-426.8%) | $74.16 M(+171.1%) | $312.81 M(+70.9%) |
| Sep 2020 | - | $27.35 M(-84.0%) | $183.00 M(-35.2%) |
| Jun 2020 | - | $170.69 M(+320.3%) | $282.52 M(+296.3%) |
| Mar 2020 | - | $40.61 M(-173.0%) | $71.28 M(-174.5%) |
| Dec 2019 | -$95.73 M(-162.5%) | -$55.66 M(-143.9%) | -$95.73 M(-148.0%) |
| Sep 2019 | - | $126.88 M(-412.9%) | $199.56 M(+105.0%) |
| Jun 2019 | - | -$40.55 M(-67.9%) | $97.35 M(+406.6%) |
| Mar 2019 | - | -$126.40 M(-152.7%) | $19.21 M(-87.5%) |
| Dec 2018 | $153.14 M(+27.7%) | $239.63 M(+871.6%) | $153.14 M(-277.1%) |
| Sep 2018 | - | $24.66 M(-120.8%) | -$86.49 M(-22.2%) |
| Jun 2018 | - | -$118.68 M(-1676.1%) | -$111.15 M(-1576.1%) |
| Mar 2018 | - | $7.53 M | $7.53 M |
| Dec 2017 | $119.92 M(-1356.2%) | - | - |
| Dec 2016 | -$9.55 M | - | - |
FAQ
- What is Amneal Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals annual FCF year-on-year change?
- What is Amneal Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals quarterly FCF year-on-year change?
- What is Amneal Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals TTM FCF year-on-year change?
What is Amneal Pharmaceuticals annual free cash flow?
The current annual FCF of AMRX is $220.11 M
What is the all time high annual FCF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high annual free cash flow is $312.81 M
What is Amneal Pharmaceuticals annual FCF year-on-year change?
Over the past year, AMRX annual free cash flow has changed by -$56.28 M (-20.36%)
What is Amneal Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of AMRX is $95.01 M
What is the all time high quarterly FCF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high quarterly free cash flow is $239.63 M
What is Amneal Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, AMRX quarterly free cash flow has changed by $0.00 (0.00%)
What is Amneal Pharmaceuticals TTM free cash flow?
The current TTM FCF of AMRX is $220.11 M
What is the all time high TTM FCF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high TTM free cash flow is $407.64 M
What is Amneal Pharmaceuticals TTM FCF year-on-year change?
Over the past year, AMRX TTM free cash flow has changed by $0.00 (0.00%)